Actively Recruiting
Evaluating ONO-2020 for Agitation in Alzheimers Disease Dementia A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Japan
Led by Ono Pharmaceutical Co., Ltd. · Updated on 2026-09-25
90
Participants Needed
39
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of ONO-2020 in treating agitation associated with Alzheimers Disease dementia in patients aged 55 to 90 years in Japan. This phase 2a, multicenter, randomized, double-blind, placebo-controlled study aims to better understand how ONO-2020 affects agitation symptoms in this population. Participants will be randomly assigned to receive either two tablets of ONO-2020 or matching placebo once daily. This treatment will continue for up to 12 weeks, with monitoring of safety and efficacy measures during and up to 16 weeks from the start. The study includes close observation for adverse events and vital signs, as well as laboratory and ECG monitoring. Throughout the trial, participants will undergo assessments including agitation severity using the Cohen-Mansfield Agitation Inventory CMAI, cognitive function tests like the Mini Mental State Exam MMSE, and neuropsychiatric evaluations. Safety will be monitored through vital signs, ECGs, laboratory tests, and the Columbia-Suicide Severity Rating Scale. The total participation period covers up to 16 weeks, including treatment and follow-up assessments.
CONDITIONS
Brief Title
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
Research Team
N
North America Clinical Trial Support Desk
I
International Clinical Trial Support Desk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here